Aivo Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aivo Biosciences is a private, preclinical biotech leveraging deep expertise in muscarinic receptor pharmacology to develop novel CNS drugs. Its lead candidate, AVB-08, is a highly potent and selective M1 agonist optimized for brain penetration and once-daily dosing, targeting a large market opportunity in schizophrenia and dementia-related psychosis. The company is led by a seasoned team with a track record in muscarinic drug development and biotech operations, aiming for rapid clinical proof-of-concept.

SchizophreniaPsychosisNeurodegenerative DiseasesNeuropathic Pain

Technology Platform

Medicinal chemistry platform for designing highly potent and selective small molecule agonists of the M1 muscarinic acetylcholine receptor, optimized for brain penetration and once-daily dosing.

Opportunities

The recent validation of the M1 muscarinic mechanism for schizophrenia creates a multi-billion dollar market opportunity for a best-in-class, selective agonist like AVB-08.

The platform also offers expansion into other high-value, large markets with significant unmet need, including Alzheimer's disease and neuropathic pain.

Risk Factors

Key risks include clinical failure of AVB-08 in human trials, intense competition from established and emerging muscarinic-targeting therapies, and reliance on raising sufficient capital in a challenging financial environment for early-stage biotechs.

Competitive Landscape

The competitive landscape is intense, led by Karuna Therapeutics' (now BMS) approved KarXT for schizophrenia. Several other biopharma companies are developing selective muscarinic agonists. Aivo's competitive edge hinges on AVB-08's high selectivity and optimized pharmacokinetic profile, which it must prove clinically.

More companies in Small Molecule Drugs →More companies in United States →